Add BrightSurf on Google Email

Science News for January 17, 2015


SPECTAcolor viable next generation multinational cancer clinical trial infrastructure

The SPECTAcolor platform has successfully implemented across 19 European clinical centers, recruiting over 500 patients and providing high-quality biological materials. Preliminary analysis reveals mutations in key cancer biomarkers, including KRAS, NRAS, BRAF, PI3K, and mismatch repair.

SourceEuropean Organisation for Research and Treatment of Cancer·JournalJournal of Clinical Oncology·DateJan 17, 2015